Open Access Open Access  Restricted Access Subscription or Fee Access

Type 2 Diabetic Dyslipidemia: A Review

Gyanendra kumar Gupta, Gagan Devi

Abstract


Diabetic dyslipidemia is a pathological condition where persistent rise in blood glucose level gives rise to derangement of lipids vis-a vis lipoproteins; which in turn increases the risk of cardiovascular diseases. Although both forms of diabetes mellitus that is, Diabetes mellitus Type-1 (insulin-dependent diabetes mellitus or IDDM) and Diabetes mellitus Type-2 (non-insulin-dependent diabetes mellitus or NIDDM) can alter lipid arrangement but Type-2 is more common (80–90%) form of diabetes mellitus, better controlled by indigenous drugs and insulin resistance is important underlying cause whereas Type-1 is less common (10–20%) form, cannot be controlled by indigenous drugs alone and genetic defect is important underlying cause. The topic chosen in the present study was Type-2 diabetic dyslipidemia.


Keywords


diabetes mellitus, diabetic dyslipidemia, lipoproteins, pathological, insulin

Full Text:

PDF

References


Edwards CRW (Eds.). Davidson's Principles and Practice of Medicine, 17th Edn. UK: Churchill Livingstone; 1995.

Boloor A, Nayak R. Exam Preparatory Manual for Undergraduates Medicine, 2nd Edn. New Delhi, India: Jaypee Brothers Medical Publishers; 2018.

Mathew KG, Aggarwal P. Manual for undergraduates Medicine, 2nd Edn. New Delhi, India: Elsevier; 2006. 883–885p.

Mohan H. Textbook of Pathology, 4th Edn. New Delhi: Jaypee Brothers Medical Publishers (Pvt.) Ltd.; 2002. 803p.

Braunwald F, Kasper H, Longo J. Harrison’s principles of internal medicine, Vol 2, 15th Edn. New York: McGraw-Hill Medical Publishing Division; 2001. 2116–2118p.

Munjal YP. API text book of medicine, Vol 1, 9th Edn. New Delhi: Jaypee Brother’s Medical Publishers (Pvt.) Ltd.; 2012. 362p, 370p, 385p.

Chehade JM, et al. Dyslipidemia in type 2 diabetes: Prevalence, pathophysiology, and management. Drugs. 2013; 73(4): 327–339p.

Goldberg IJ. Diabetic Dyslipidemia: Causes and Consequences. The Journal of Clinical Endocrinology & Metabolism. 2001; 86(3): 965–971p.

Duff G, MacMillan G. The effect of alloxan diabetes on experimental atherosclerosis in the rabbit. J Exp Med. 1949; 89: 611–630p.

Steiner G. Lipid intervention trials in diabetes. Diabetes Care. 2000; 23 (Suppl 2): B49–B53.




DOI: https://doi.org/10.37591/rrjomst.v10i2.2606

Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Research & Reviews: Journal of Medical Science and Technology